5 REASONS TO ATTEND DIA'S ADVANCING THE SCIENCE OF STUDY ENDPOINTS CONFERENCE

1. **HEAR** updates from FDA on:
   - The Qualification of Drug Development Tools program mandated by 21st Century Cures Act
   - The use of Clinical Outcome Assessments in oncology clinical trials
   - How FDA's Patient-Focused Drug Development is impacting endpoint selection, design, and validation
2. **DISCUSS** the needs and requirements of critical stakeholders for study endpoint data — patients, regulatory agencies, clinicians, and payers
3. **OBTAIN** updates from the C-Path PRO Consortium
4. **LEARN** about DIA's Study Endpoints Community and how to propose and join Scientific Working Groups
5. **NETWORK** with experts involved in endpoint development and clinical outcomes

RELEVANT RESOURCES

FDA

- Drug Development Tool Programs and Initiatives
- Patient-Focused Drug Development
- Clinical Outcome Assesment Qualification Program

EMA

- Qualification of Novel Methodologies for Medicine Development

Other

- DIA Study Endpoints Community
- EUPATI Patient Reported Outcomes (PRO) Assessments
- IMI PROactive Project
- C-Path PRO Consortium
- C-Path ePRO Consortium
- CTTI Novel Endpoints Project

Advancing the Science of Study Endpoints
September 20-21

REGISTER NOW